COLLEGIUM PHARMACEUTICAL, INC - 8-K Filing
Collegium Pharmaceutical completed an acquisition on May 12, 2026 for $650 million in cash to acquire AZSTARYS, a prescription medicine for ADHD. The deal was funded with $350 million from existing cash and $300 million via a delayed draw term loan. Additionally, the company announced leadership changes as Scott Dreyer (Chief Commercial Officer) will depart by August 30, 2026, and Thomas Smith (Chief Medical Officer) is transitioning out following a search for his successor. (Items: 2.01 Completion of Acquisition or Disposition of Assets, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $COLL